Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Midatech Pharma Plc - news published 64 - readings 3.336

BACK

Midatech Pharma plc

Proposed Acquisition of Bioasis Technologies Inc

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 13 December 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 13 December 2022 15:30:20 UTC .

13.12.2022

Midatech Pharma plc

First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with - Form 6-K

First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the enrolment of the first patient into its Phase 1 study of MTX110 in recurrent glioblastoma ( ...

14.11.2022

Midatech Pharma plc

Registration Statement by Foreign Issuer - Specific Transactions - Form F-3

As filed with the Securities and Exchange Commission on October 18, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MIDATECH PHARMA PLC (Exact name of registrant as specified in its charter) Not Applicable (Translation of registrant's name into English) England a ...

18.10.2022

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Filed pursuant to Rule 424(b)(3) Registration No.: 333-240984 PROSPECTUS SUPPLEMENT MIDATECH PHARMA PLC 9,888,640 Ordinary Shares Representing 1,977,728 American Depositary Shares This prospectus supplement (the "Prospectus Supplement") amends and supplements our prospectus contained in our Post-Effective Amendment No. 2 to our Registration Statement on Form F-1, eff ...

04.10.2022

Midatech Pharma plc

EXPLANATORY NOTE - Form 6-K/A

EXPLANATORY NOTE This Amendment No. 1 to the Report on Form 6-K for the month of September 2022, originally filed with the U.S. Securities and Exchange Commission on September 14, 2022 (the "Form 6-K"), is being filed solely for the purposes of updating Exhibit 99.1 to include iXBRL tagging information. Other than as expressly set forth above, this Form 6-K/A does no ...

04.10.2022

Midatech Pharma plc

Holding(s) in Company

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 20 September 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 20 September 2022 11:02:21 UTC .

20.09.2022

Midatech Pharma plc

ADR Ratio Change - Form 6-K

ADR Ratio Change Midatech Pharma (AIM: MTPH; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing five (5) ordinary shares, to the new ratio of one (1) ADR representing twenty-five (25) ordinary shares (t ...

14.09.2022

Midatech Pharma plc

ADR Ratio Change

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 14 September 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 14 September 2022 13:22:10 UTC .

14.09.2022

Midatech Pharma plc

Current Report by Foreign Issuer - Form 6-K

14 September 2022 Midatech Pharma Plc ("Midatech" or the "Company") Interim results for the six months ended 30 June 2022 Midatech Pharma Plc (AIM: MTPH; NASDAQ: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its unaudited interim results for the six months ended 30 June 2022 which ...

14.09.2022

Midatech Pharma plc

Interim Report 2022

MIDATECH PHARMA PLC INTERIM RESULTS Six months ended 30 June 2022 Company number 09216368 14 September 2022 Midatech Pharma Plc ("Midatech" or the "Company") Interim results for the six months ended 30 June 2022 Midatech Pharma Plc (AIM: MTPH; NASDAQ: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medic ...

14.09.2022

Midatech Pharma plc

Investigational New Drug Application for Study of MTX110 - Form 6-K

Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that its Investigational New Drug (IND) application for a Phase 1 study of MTX110, a panobinosta ...

13.12.2021

Midatech Pharma plc

Post-effective Amendment to Registration Statement for Employee Benefit Plan (SEC Filing - S-8 POS)

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 27, 2021 Registration No. 333-214969 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Midatech Pharma PLC (Exact name of registrant as specified in its charter) England and Wales Not Applicabl ...

27.09.2021

Midatech Pharma plc

Supplemental Prospectus (SEC Filing - 424B3)

Filed pursuant to Rule 424(b)(3) Registration No.: 333-240984 PROSPECTUS SUPPLEMENT MIDATECH PHARMA PLC 12,695,456 Ordinary Shares Representing 2,539,091 American Depositary Shares This prospectus supplement (the "Prospectus Supplement") amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to our Registration Statement on Form F-1, ef ...

21.09.2021

Midatech Pharma plc

Interim Report 2021

MIDATECH PHARMA PLC INTERIM RESULTS Six months ended 30 June 2021 Company number 09216368 1 17 September 2021 Midatech Pharma Plc ("Midatech" or the "Company") Interim results for the six months ended 30 June 2021 Midatech Pharma PLC (AIM: MTPH.L; NASDAQ: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of m ...

17.09.2021

Midatech Pharma plc

Result of 2021 Annual General Meeting (Form 6-K)

Result of 2021 Annual General Meeting Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that at its Annual General Meeting (AGM) held at 11.30am today all resolutions put to the meeting were duly passed. For more information, please contact: Midatech Pharma PLC St ...

18.08.2021

Midatech Pharma Plc - news published 64 - readings 3.336

Midatech Pharma plc

Proposed Acquisition of Bioasis Technologies Inc

Midatech Pharma plc

First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with - Form 6-K

Midatech Pharma plc

Registration Statement by Foreign Issuer - Specific Transactions - Form F-3

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Midatech Pharma plc

EXPLANATORY NOTE - Form 6-K/A

Midatech Pharma plc

Holding(s) in Company

Midatech Pharma plc

ADR Ratio Change - Form 6-K

Midatech Pharma plc

ADR Ratio Change

Midatech Pharma plc

Current Report by Foreign Issuer - Form 6-K

Midatech Pharma plc

Interim Report 2022

Midatech Pharma plc

Investigational New Drug Application for Study of MTX110 - Form 6-K

Midatech Pharma plc

Post-effective Amendment to Registration Statement for Employee Benefit Plan (SEC Filing - S-8 POS)

Midatech Pharma plc

Supplemental Prospectus (SEC Filing - 424B3)

Midatech Pharma plc

Interim Report 2021

Midatech Pharma plc

Result of 2021 Annual General Meeting (Form 6-K)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member